Dr. Galsky on how recurrence impacts QOL in muscle-invasive UC

“Recurrence of urothelial cancer, in particular metastatic recurrence, is associated with a detriment in quality of life in this exploratory analysis,” says Matthew Galsky, MD.

In a video filmed during the 2021 ASCO Annual Meeting, Matthew Galsky, MD, discusses shares the take-home message from the abstract, “Impact of recurrence on health-related quality of life in patients at high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trial.” Galsky is Professor of Medicine (Hematology and Medical Oncology) and Acting Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System, New York City, New York.